Page 1

Global Multiple Sclerosis Drugs Market was Valued at US$ 20.13 Bn in 2025, Growing Awareness about the Disease Analyst Speak: “The Global Multiple Sclerosis Drugs Market was valued around US$ 20.13 Bn by 2025 and growing at

a significant CAGR of 9.2% over next seven years 2019-2025 owing to growing awareness about the disease� The global multiple sclerosis drugs market accounted for US$ XX Mn in 2018 and burgeoning over the forthcoming years. Factors which are influencing the market growth are growing research in the field of MS to develop innovative therapies, increasing awareness about the disease and rising healthcare expenditures. However, high cost related with treatment of drugs, lack of availability of drugs and stringent regulatory approvals are hampering the market growth. Moreover, technological advancements in biomedical science and new product launches would act as major opportunities for the market growth. Global multiple sclerosis drugs market segmented on the basis of drug class, route of administration, distribution channel, and region.

For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15731

Orally Administrated Products Dominate the Global Multiple Sclerosis Drugs Market Based on route of administration, global multiple sclerosis drugs market segmented into parenteral and oral. Oral segment held considerable market growth during estimated period. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. Several oral treatments have shown benefit and will generate much interest because of the convenience of such administration. New oral drugs recently approved for MS treatment represent significant advances in therapy. Three oral drugs have been approved by regulatory agencies for MS treatment such as fingolimod, teriflunomide, and dimethyl fumarate. Thus, increasing the segment demand in this market.

North America Leads the Global Multiple Sclerosis Drugs market PBI’s global multiple sclerosis drugs market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. This region is one of the key markets for multiple sclerosis drugs. The region has witnessed considerable growth in this market owing to the supportive medical reimbursement policies, huge sales of multiple sclerosis drugs in countries such as the U.S. and Canada. Asia Pacific is expected to grow with a steady growth rate due to increasing investments made by major market players in therapeutic drugs, introducing new products and rising patient with this disease in countries such as Japan and China.

New Product Launch are the Key Strategies Adopted by Market Players Global multiple sclerosis drugs market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, in 2018, Sanofi launched multiple sclerosis treatment drug in India. This product has the potential to offer an efficacious


and convenient treatment regimen of just once a day oral tablet, vis-a-vis commonly available injectable treatment options. Key player’s profiles in the report are Teva Pharmaceutical industries Ltd. (Israel), Sanofi S.A. (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Medtronic plc (Questcor Pharmaceuiticals) (U.S.), Biogen, Inc. (U.S.), Bayer AG (Germany), Acorda Therapeuitics (U.S.) and GlaxoSmithKline. Precision Business Insights (PBI) in its report titled “Global Multiple Sclerosis Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.

Detailed Segmentation By Drug Class o Steroids o Others o Disease Modifying Drugs (DMDs) By Route of Administration o Parenteral o Oral By Distribution Channel o Retail Pharmacy o Online Pharmacy o Hospital Pharmacy By Geography o North America  U.S  Canada o Europe  Germany  France  U.K  Italy  Spain  Russia  Poland  Rest of Europe o Asia-Pacific  Japan  China  India


 

o

o

Australia & New Zealand ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)  South Korea  Rest of Asia-Pacific Latin America  Brazil  Mexico  Argentina  Rest of Latin America Middle East and Africa (MEA)  Gulf Cooperation Council (GCC) Countries  Israel  South Africa  Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-multiplesclerosis-drugs-market/ Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

Kemp House, 152 – 160 City Road, London EC1V 2NX Email: sales@precisionbusinessinsights.com Toll Free (US): +1-866-598-1553 Website @ https://www.precisionbusinessinsights.com

Profile for rekhamuthyala2

Multiple Sclerosis Drugs Market Size, Share, Growth, and Forecast to 2025  

The global multiple sclerosis drugs market accounted for US$ XX Mn in 2018 and burgeoning over the forthcoming years. Factors which are infl...

Multiple Sclerosis Drugs Market Size, Share, Growth, and Forecast to 2025  

The global multiple sclerosis drugs market accounted for US$ XX Mn in 2018 and burgeoning over the forthcoming years. Factors which are infl...

Advertisement